Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
PDF) mRNA vaccines — a new era in vaccinology
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Moncef Slaoui - Wikipedia
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Crowd fund launched for 'Battlestar Galactica' actor Michael Hogan after brain injury
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
